Literature DB >> 15254579

Progress and problems in the biology, diagnostics, and therapeutics of prion diseases.

Adriano Aguzzi1, Mathias Heikenwalder, Gino Miele.   

Abstract

The term "prion" was introduced by Stanley Prusiner in 1982 to describe the atypical infectious agent that causes transmissible spongiform encephalopathies, a group of infectious neurodegenerative diseases that include scrapie in sheep, Creutzfeldt-Jakob disease in humans, chronic wasting disease in cervids, and bovine spongiform encephalopathy in cattle. Over the past twenty years, the word "prion" has been taken to signify various subtly different concepts. In this article, we refer to the prion as the transmissible principle underlying prion diseases, without necessarily implying any specific biochemical or structural identity. When Prusiner started his seminal work, the study of transmissible spongiform encephalopathies was undertaken by only a handful of scientists. Since that time, the "mad cow" crisis has put prion diseases on the agenda of both politicians and the media. Significant progress has been made in prion disease research, and many aspects of prion pathogenesis are now understood. And yet the diagnostic procedures available for prion diseases are not nearly as sensitive as they ought to be, and no therapeutic intervention has been shown to reliably affect the course of the diseases. This article reviews recent progress in the areas of pathogenesis of, diagnostics of, and therapy for prion diseases and highlights some conspicuous problems that remain to be addressed in each of these fields.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254579      PMCID: PMC449758          DOI: 10.1172/JCI22438

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  93 in total

1.  Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol.

Authors:  Jiyan Ma; Susan Lindquist
Journal:  Science       Date:  2002-10-17       Impact factor: 47.728

2.  Postexposure prophylaxis against prion disease with a stimulator of innate immunity.

Authors:  Shneh Sethi; Grayson Lipford; Hermann Wagner; Hans Kretzschmar
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321

3.  Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.

Authors:  Philipp Meier; Nicolas Genoud; Marco Prinz; Manuela Maissen; Thomas Rülicke; Andreas Zurbriggen; Alex J Raeber; Adriano Aguzzi
Journal:  Cell       Date:  2003-04-04       Impact factor: 41.582

4.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

5.  Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol.

Authors:  Jiyan Ma; Robert Wollmann; Susan Lindquist
Journal:  Science       Date:  2002-10-17       Impact factor: 47.728

6.  Transmission of prion diseases by blood transfusion.

Authors:  Nora Hunter; James Foster; Angela Chong; Sandra McCutcheon; David Parnham; Samantha Eaton; Calum MacKenzie; Fiona Houston
Journal:  J Gen Virol       Date:  2002-11       Impact factor: 3.891

7.  Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice.

Authors:  Jiri G Safar; Michael Scott; Jeff Monaghan; Camille Deering; Svetlana Didorenko; Julie Vergara; Haydn Ball; Giuseppe Legname; Estelle Leclerc; Laura Solforosi; Hana Serban; Darlene Groth; Dennis R Burton; Stanley B Prusiner; R Anthony Williamson
Journal:  Nat Biotechnol       Date:  2002-10-21       Impact factor: 54.908

8.  Prion pathogenesis in the absence of Toll-like receptor signalling.

Authors:  Marco Prinz; Mathias Heikenwalder; Petra Schwarz; Kiyoshi Takeda; Shizuo Akira; Adriano Aguzzi
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

9.  A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions.

Authors:  P-C Klöhn; L Stoltze; E Flechsig; M Enari; C Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

10.  Oral prion infection requires normal numbers of Peyer's patches but not of enteric lymphocytes.

Authors:  Marco Prinz; Gerhard Huber; Andrew J S Macpherson; Frank L Heppner; Markus Glatzel; Hans-Pietro Eugster; Norbert Wagner; Adriano Aguzzi
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

View more
  19 in total

1.  Generation of antisera to purified prions in lipid rafts.

Authors:  Robert Hnasko; Ana V Serban; George Carlson; Stanley B Prusiner; Larry H Stanker
Journal:  Prion       Date:  2010-04-09       Impact factor: 3.931

2.  Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies.

Authors:  Gaetano Donofrio; Frank L Heppner; Magdalini Polymenidou; Christine Musahl; Adriano Aguzzi
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Sporadic Creutzfeldt-Jakob disease with cerebellar ataxia at onset in the UK.

Authors:  S A Cooper; K L Murray; C A Heath; R G Will; R S G Knight
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-07-11       Impact factor: 10.154

Review 4.  Quantum dots and prion proteins: is this a new challenge for neurodegenerative diseases imaging?

Authors:  Pavlina Sobrova; Iva Blazkova; Jana Chomoucka; Jana Drbohlavova; Marketa Vaculovicova; Pavel Kopel; Jaromir Hubalek; Rene Kizek; Vojtech Adam
Journal:  Prion       Date:  2013-09-20       Impact factor: 3.931

5.  Prions Strongly Reduce NMDA Receptor S-Nitrosylation Levels at Pre-symptomatic and Terminal Stages of Prion Diseases.

Authors:  Elisa Meneghetti; Lisa Gasperini; Tommaso Virgilio; Fabio Moda; Fabrizio Tagliavini; Federico Benetti; Giuseppe Legname
Journal:  Mol Neurobiol       Date:  2019-02-01       Impact factor: 5.590

6.  Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells.

Authors:  Valentina Villa; Stefano Thellung; Alessandro Corsaro; Federica Novelli; Bruno Tasso; Luca Colucci-D'Amato; Elena Gatta; Michele Tonelli; Tullio Florio
Journal:  Mol Neurobiol       Date:  2014-11-18       Impact factor: 5.590

7.  Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.

Authors:  Alexander Pfeifer; Sabina Eigenbrod; Saba Al-Khadra; Andreas Hofmann; Gerda Mitteregger; Markus Moser; Uwe Bertsch; Hans Kretzschmar
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

8.  Antiprion activity of cholesterol esterification modulators: a comparative study using ex vivo sheep fibroblasts and lymphocytes and mouse neuroblastoma cell lines.

Authors:  Alessandra Pani; Claudia Norfo; Claudia Abete; Claudia Mulas; Marirosa Putzolu; Sergio Laconi; Christina Doriana Orrù; M Dolores Cannas; Sarah Vascellari; Paolo La Colla; Sandra Dessì
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

9.  Surgery and risk of sporadic Creutzfeldt-Jakob disease in Denmark and Sweden: registry-based case-control studies.

Authors:  Ignacio Mahillo-Fernandez; Jesús de Pedro-Cuesta; Maria José Bleda; Mabel Cruz; Kåre Mølbak; Henning Laursen; Gerhard Falkenhorst; Pablo Martínez-Martín; Ake Siden
Journal:  Neuroepidemiology       Date:  2008-10-09       Impact factor: 3.282

10.  Treatment of SMB-S15 Cells with Resveratrol Efficiently Removes the PrP(Sc) Accumulation In Vitro and Prion Infectivity In Vivo.

Authors:  Jing Wang; Bao-Yun Zhang; Jin Zhang; Kang Xiao; Li-Na Chen; Hui Wang; Jing Sun; Qi Shi; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2015-10-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.